CDER Product-Specific Guidances Withdrawn Listing

Updated July 24th, 2024

Active Ingredient	Type of Guidance	Route and Dosage Form	RLD	Date PSG posted or revised	FEDERAL REGISTER Notice Date
Butenafine Hydrochloride	Draft	Topical Cream	021408	3/1/2012	2/1/2015
Hydroxyprogesterone Caproate	Draft	Subcutaneous Solution	021945	9/16/2019	4/6/2023
Levonorgestrel	Draft	Intrauterine Device	203159	4/1/2014	10/1/2014
Lorcaserin Hydrochloride	Draft	Oral Tablet, Extended Release	022529	3/1/2015	3/4/2021
Lorcaserin Hydrochloride	Draft	Oral Tablet, Extended Release	208524	5/1/2017	3/4/2021
Lovastatin; Niacin	Draft	Oral Tablet, Extended Release	021249	7/1/2009	4/18/2016
Melphalan Flufenamide Hydrochloride	Draft	Intravenous Powder	214383	11/17/2022	4/18/2024
Niacin; Simvastatin	Draft	Oral Tablet, Extended Release	022078	10/1/2011	4/18/2016
Oxymorphone Hydrochloride	Draft	Oral Tablet, Extended Release	201655	10/04/2016	12/23/2020